Answers are grounded in this paper and cite their sources.
Objective: Stress hyperglycemia (SH) is simply assessed by calculating the stress hyperglycemia ratio (SHR). This study aimed to calculate the SHR in type 2 diabetes (T2D) patients receiving oral diabetes medications that worked through two different mechanisms. Materials and methods: This open-label randomized clinical trial was conducted in the College of Medicine, University of Diyala, Baqubah, Iraq, from January 1, 2022, to December 31, 2022. Patients with T2D without a previous history of surgical procedures and with no acute or chronic infections were randomly assigned to receive sitagliptin/metformin 50/500 mg or empagliflozin/metformin 10/500 mg orally once daily. Patients were randomized in-hospital, and treated for up to 10 weeks. The primary outcome of this open-label clinical trial was SH, defined as the estimated plasma glucose, and SHR values. The secondary outcome included hematological indices and C-reactive protein (CRP). Results: Eighty patients with T2D were enrolled in the study and divided into two groups. Group I (n = 40) received sitagliptin/metformin, and Group II (n = 40) received empagliflozin/metformin. The baseline data showed non-significant difference between the two groups in the SH and SHR. The median values of SHR decreased by 9.2% (0.925 vs. 0.840, p = 0.047) in Group I compared with an 8.7% decrease (0.940 vs. 0.858, p = 0.113) in Group II patients. The median values of CRP were non-significantly decreased in Group I (6.0 vs. 5.3 mg/dL, p = 0.507) and remained unchanged in Group II (3.4 vs. 3.4 mg/dL, p = 0.769). Conclusions: Sitagliptin has a better effect against stress hyperglycemia ratio than empagliflozin.
No takes yet. Share an insight, caveat, or question.
Al-Nimer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: